A new digital therapy designed to treat depression will soon be available in France.
- Depression is a mental disorder characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-esteem, trouble sleeping or eating, feeling tired and a lack of focus.
- It can be long-lasting or recurring.
Already reimbursed in Germany, the new deprexis® digital therapy for adults suffering from depression will soon be available in France. Developed by international specialists, its effectiveness has been repeatedly demonstrated in 12 randomized controlled trials.
A duration of 3 months
Based on cognitive-behavioral therapies (CBT), it can be recommended by a doctor for a period of 3 months in addition to the usual treatment. Thanks to artificial intelligence, the program is personalized according to the patient and their interactions. 10 modules simulate dialogues through questionnaires, illustrations, worksheets, audio recordings, videos, sms, etc…
According to Dr. Jan Philipp Klein, a psychiatrist from the University of Lübeck (Germany), who has conducted several evaluations of deprexis®, “The use of this digital therapy makes it possible, on the one hand, to treat half of the patients suffering from depression that healthcare professionals are currently unable to reach, and on the other hand, it improves the outcome when it is used as an adjunct to current treatments for depression. Reimbursement of deprexis® and other digital therapies in Germany marks a real breakthrough in the treatment of depression.”
One in five French people concerned
deprexis® has also been shown to reduce co-associated depressive symptoms in patients with multiple sclerosis, epilepsy and gambling addiction. Finally, a pharmaco-economic study has demonstrated the significant reduction in the cost of treating depression thanks to this new digital therapy.
Depression will affect one in five people in France during their lifetime. Figures amplified by the health crisis, which has made mental health a priority for health authorities and the Government.
.
